Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss

DOI Web Site 43 References
  • Kubota Takuo
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Namba Noriyuki
    Department of Pediatrics, Osaka University Graduate School of Medicine The First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry
  • Kurotobi Shunji
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Kogaki Shigetoyo
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Hirai Haruhiko
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Kitaoka Taichi
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Nakajima Shigeo
    Department of Pediatrics, Osaka University Graduate School of Medicine
  • Ozono Keiichi
    Department of Pediatrics, Osaka University Graduate School of Medicine

Search this article

Abstract

Bisphosphonate is widely used to treat patients with primary and secondary osteoporosis. The chronic administration of furosemide is considered a risk factor for osteoporosis mainly due to the increased urinary excretion of calcium, leading to a long-term negative balance of calcium. We describe two patients with mild heart failure who took furosemide for more than 5 yr and developed hyperparathyroidism and lumbago associated with low bone mineral density. Their serum levels of intact parathyroid hormone and bone mineral density (BMD) of the lumbar spine (L2-L4) were 180.8 and 144.3 pg/ml, and 71% and 80% of the mean of healthy women, respectively. The oral administration of alendronate or risedronate was effective for lumbago and improved BMD, although the urinary excretion of calcium and hyperparathyroidism were not changed. For the medical treatment of lumbago and decreased bone mass secondary to the long-term administration of furosemide, bisphosphonate is proposed when the dose of furosemide cannot be reduced. However, it may be important to give sufficient calcium and vitamin D to patients to improve secondary hyperparathyroidism.<br>

Journal

References(43)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top